Hidradenitis Suppurativa
FDA Accepts UCB’s sBLA for 2 mL Bimzelx Device
April 22, 2024
FDA Accepts UCB’s sBLA for Bimzelx in HS
April 22, 2024
EC Green Lights Bimzelx for HS
April 22, 2024
Incyte’s Topical JAK Shows Promise in Milder HS
March 12, 2024
Novartis’ BTK Inhibitor Outpaces Placebo in HS Trial
March 9, 2024